Annexon, Inc. is a high-risk pharmaceutical company in the United States focused on developing innovative therapies for classical complement-mediated disorders of the body, brain, and eye. Using its ESG-based platform technology, Annexon aims to address autoimmune and neurodegenerative diseases triggered by abnormal activation of C1q. The company's product candidates such as ANX005, ANX007, ANX1502, and ANX009 target various complement-mediated diseases by blocking the activity of C1q and the classical complement pathway.